← GLP-1 receptor agonists × cardiovascular events

Observational studyOpen heart2025

Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.

Takefumi Kishimori et al.PubMed ↗Full text ↗Publisher ↗

  • Semaglutidelooks good hereFewer deaths, no clear effect on acute myocardial infarction, no clear effect on stroke.Randomised, small.

What the trial testedrandomised · 750 people · 2025

Randomised vs sitagliptin

Probably reduced deaths

−24%−30% to −17%

semaglutide vs sitagliptin

Bigger than 7 in 10 for all-cause mortality

As reported

HR 0.76, 95% CI 0.70–0.83 · the paper's word: all-cause death

Range includes no effect

No clear effect on acute myocardial infarction

+1%−7% to +9%

semaglutide vs sitagliptin

Smaller than almost all for cardiovascular events

As reported

HR 1.01, 95% CI 0.93–1.09

Range includes no effect

No clear effect on stroke

+2%−6% to +10%

semaglutide vs sitagliptin

Smaller than almost all for cardiovascular events

As reported

HR 1.02, 95% CI 0.94–1.10

Who was studied, and how

750people with type 2 diabetes, aged 18+, in this paper

The trial randomly assignedassigned by chance

semaglutide
sitagliptin

Probably reduced deaths−24%

No clear effect on acute myocardial infarction+1%

No clear effect on stroke+2%

randomised

the abstract, start to end

… 703) vs 9.5% (1196/13 703); p<0.001; HR, 0.76; 95% CI, 0.70 to 0.83).

… were not significant (9.6% vs 9.5%; HR, 1.01; 95% CI, 0.93 to 1.09 in acute myocardial infarction, and 9.2% vs 9.0%; HR, 1.02; 95% CI, 0.94 to 1.10 in …

← favours treatmentfavours comparator →
could be chance
All-cause deathsemaglutide vs sitagliptin
HR 0.760.70–0.83
Acute myocardial infarctionsemaglutide vs sitagliptin
HR 1.010.93–1.09
Strokesemaglutide vs sitagliptin
HR 1.020.94–1.10
GLP-1 receptor agonistsCardiovascular eventsAll-cause mortality
1 / 4

1 paper cites it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40628673